These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 17916461

  • 1. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B, Ball G, Rees R.
    Vaccine; 2007 Sep 27; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [Abstract] [Full Text] [Related]

  • 2. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA.
    J Proteome Res; 2008 Aug 27; 7(8):3146-58. PubMed ID: 18553995
    [Abstract] [Full Text] [Related]

  • 3. Proteomics in prostate cancer biomarker discovery.
    Larkin SE, Zeidan B, Taylor MG, Bickers B, Al-Ruwaili J, Aukim-Hastie C, Townsend PA.
    Expert Rev Proteomics; 2010 Feb 27; 7(1):93-102. PubMed ID: 20121479
    [Abstract] [Full Text] [Related]

  • 4. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR, Liotta LA, Petricoin EF.
    Biosci Rep; 2005 Feb 27; 25(1-2):107-25. PubMed ID: 16222423
    [Abstract] [Full Text] [Related]

  • 5. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A, Ma PC, Salgia R.
    Mass Spectrom Rev; 2007 Feb 27; 26(3):451-66. PubMed ID: 17407130
    [Abstract] [Full Text] [Related]

  • 6. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C, Liotta LA, Petricoin EF.
    Crit Rev Clin Lab Sci; 2010 Feb 27; 47(3):125-38. PubMed ID: 20858067
    [Abstract] [Full Text] [Related]

  • 7. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK, Tyson DR.
    Urol Oncol; 2006 Feb 27; 24(3):231-6. PubMed ID: 16678055
    [Abstract] [Full Text] [Related]

  • 8. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ, Febbo PG.
    Oncologist; 2009 Aug 27; 14(8):816-27. PubMed ID: 19684076
    [Abstract] [Full Text] [Related]

  • 9. Mass spectrometry: uncovering the cancer proteome for diagnostics.
    van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP.
    Adv Cancer Res; 2007 Aug 27; 96():23-50. PubMed ID: 17161675
    [Abstract] [Full Text] [Related]

  • 10. Proteome informatics for cancer research: from molecules to clinic.
    Brusic V, Marina O, Wu CJ, Reinherz EL.
    Proteomics; 2007 Mar 27; 7(6):976-91. PubMed ID: 17370257
    [Abstract] [Full Text] [Related]

  • 11. Clinical proteomics in breast cancer: a review.
    Gast MC, Schellens JH, Beijnen JH.
    Breast Cancer Res Treat; 2009 Jul 27; 116(1):17-29. PubMed ID: 19082706
    [Abstract] [Full Text] [Related]

  • 12. Cancer biomarkers: knowing the present and predicting the future.
    Chatterjee SK, Zetter BR.
    Future Oncol; 2005 Feb 27; 1(1):37-50. PubMed ID: 16555974
    [Abstract] [Full Text] [Related]

  • 13. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G, Jung K, Stephan C, Diamandis EP.
    J Proteome Res; 2008 Aug 27; 7(8):3329-38. PubMed ID: 18578523
    [Abstract] [Full Text] [Related]

  • 14. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ, Lee DI.
    Urol Oncol; 2008 Aug 27; 26(6):576-80. PubMed ID: 18996314
    [Abstract] [Full Text] [Related]

  • 15. The role of proteomics in prostate cancer research: biomarker discovery and validation.
    Pin E, Fredolini C, Petricoin EF.
    Clin Biochem; 2013 Apr 27; 46(6):524-38. PubMed ID: 23266295
    [Abstract] [Full Text] [Related]

  • 16. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
    Christensen E, Evans KR, Ménard C, Pintilie M, Bristow RG.
    Cancer Metastasis Rev; 2008 Sep 27; 27(3):375-85. PubMed ID: 18427732
    [Abstract] [Full Text] [Related]

  • 17. Biomarkers for the development of cancer vaccines: current status.
    Copier J, Whelan M, Dalgleish A.
    Mol Diagn Ther; 2006 Sep 27; 10(6):337-43. PubMed ID: 17154650
    [Abstract] [Full Text] [Related]

  • 18. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM.
    J Urol; 2007 Apr 27; 177(4):1229-37. PubMed ID: 17382696
    [Abstract] [Full Text] [Related]

  • 19. Oral cancer proteomics.
    Hu S, Wong DT.
    Curr Opin Mol Ther; 2007 Oct 27; 9(5):467-76. PubMed ID: 17932810
    [Abstract] [Full Text] [Related]

  • 20. Proteomics: new technologies and clinical applications.
    Latterich M, Abramovitz M, Leyland-Jones B.
    Eur J Cancer; 2008 Dec 27; 44(18):2737-41. PubMed ID: 18977654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.